John L. Berk, MD
Associate Professor
Boston University School of Medicine
Dept of Medicine
Pulmonary, Allergy, Sleep & Critical Care Medicine

MD, Case Western Reserve University



Expertise in Amyloidosis with specific emphasis in Familial and localized amyloid disease; pulmonary fibrosis.


EXPANDED ACCESS PROTOCOL OF PATISIRAN FOR PATIENTS WITH HEREDITARY TRANSTHYRETIN-MEDIATED AMYLOIDOSIS (HATTR AMYLOIDOSIS) WITH POLYNENROPATHY
10/31/2016 - 10/30/2021 (PI)
Alnylam Pharmaceuticals, Inc.

PROTOCOL ISIS 420915-CS4, A NON-INTERVENTIONAL STUDY TO MONITOR THE SURVIVAL STATUS OF PATIENTS THAT DISCONTINUED FROM ISIS 420915-CS2 OR ISIS 420915-CS3
05/14/2018 - 05/13/2021 (PI)
Ionis Pharmaceuticals, Inc.

PROTOCOL CS5 - EXPANDED ACCESS PROGRAM FOR INOTERSEN (ISIS 420915) IN PATIENTS WITH HEREDITARY TRANSTHYRETIN AMYLOIDOSIS (HATTR)
04/17/2018 - 04/16/2021 (PI)
Ionis Pharmaceuticals, Inc.

PROTOCOL EIDOS AG10-101, ASSESSMENT OF THE TTR BINDING AND STABILIZING PROPERTIES OF AG10 TO DIFFERENT VARIANT TTRS IN THE SERA OR PLASMA FROM ATTR PATIENTS OR RELATIVES WITH DIFFERENT TTR GENOTYPES
03/05/2018 - 03/04/2021 (PI)
Eidos Therapeutics, Inc.

PROTOCOL AG10-201, A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING STUDY OF THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AG10 IN PATIENTS WITH SYMPTOMATIC TRANSTHYRETIN
03/05/2018 - 03/04/2021 (PI)
Eidos Therapeutics, Inc.

A PHASE 3 MULTICENTER, MULTINATIONAL, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLE STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ALN-TTRSC IN PATIENTS WITH TRANSTHYRETIN MEDIATED FAMILIAL AMYLOIDOTIC
07/28/2015 - 07/28/2020 (PI)
Alnylam Pharmaceuticals, Inc.

A PHASE 3 MULTICENTER, RANDOMIZED, DOUBLE-BLIND, EXTENSION STUDY TO EVALUATE THE SAFETY OF DAILY ORAL DOSING OF TAFAMIDIS MEGLUMINE (PF-06291826) 20 MG OR 80 MG IN SUBJECTS DIAGNOSED WITH TRANSTHYRETI
04/04/2017 - 04/03/2020 (PI)
Pfizer, Inc.

AN OPEN-LABEL EXTENSION STUDY TO ASSESS THE LONG-TERM SAFETY AND EFFICACY OF ISIS 420915 IN PATIENTS WITH FAMILIAL AMYLOID POLYNEUROPATHY
09/30/2014 - 09/30/2019 (PI)
Ionis Pharmaceuticals, Inc.

MULTICENTER, OPEN-LABEL, EXTENSION STUDY TO EVALUATE THE LONG-TERM SAFETY AND EFFICACY OF PATISIRAN IN PATIENTS WITH FAMILIAL AMYLOIDOTIC POLYNEUROPATHY WHO HAVE COMPLETED A PRIOR CLINICAL STUDY WITH
03/29/2016 - 03/28/2019 (PI)
Alnylam Pharmaceuticals, Inc.

TREATMENT USE OF EPRODISATE (KLACTA) IN A PATIENT DIAGNOSED WITH AA AMYLOIDOSIS
02/16/2016 - 02/15/2019 (PI)
A.T. Development Switzerland Sarl

Showing 10 of 21 results. Show All Results



Yr Title Project-Sub Proj Pubs
2009 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-05 9
2008 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-04 9
2007 THE EFFECT OF DIFLUNISAL ON HEREDITARY AMYLOIDOSIS 2M01RR000533-39-8163 429
2007 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-03 9
2007 Effect of diflunisal on familial amyloidosis 5R01FD002532-03 2
2006 Effect of diflunisal (IND68092) on familial amyloidosis 5R01NS051306-02 9
2006 Effect of diflunisal on familial amyloidosis 5R01FD002532-02 2
2005 Effect of diflunisal (IND68092) on familial amyloidosis 1R01NS051306-01 9
2001 ADRENAL INSUFFICIENCY IN PRIMARY SYSTEMIC AMYLOIDOSIS 5M01RR000533-33-353 429
2000 ADRENAL INSUFFICIENCY IN PRIMARY SYSTEMIC AMYLOIDOSIS 5M01RR000533-32-353 429
Showing 10 of 15 results. Show All Results
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. Waddington-Cruz M, Ackermann EJ, Polydefkis M, Heitner SB, Dyck PJ, Barroso FA, Wang AK, Berk JL, Dyck PJB, Monia BP, Hughes SG, Tai L, Jesse Kwoh T, Jung SW, Coelho T, Benson MD, Gertz MA. Hereditary transthyretin amyloidosis: baseline characteristics of patients in the NEURO-TTR trial. Amyloid. 2018 Aug 31; 1-9. PMID: 30169969.
     
  2. Giadone RM, Rosarda JD, Akepati PR, Thomas AC, Boldbaatar B, James MF, Wilson AA, Sanchorawala V, Connors LH, Berk JL, Wiseman RL, Murphy GJ. A library of ATTR amyloidosis patient-specific induced pluripotent stem cells for disease modelling and in vitro testing of novel therapeutics. Amyloid. 2018 Jul 21; 1-8.View Related Profiles. PMID: 30032658.
     
  3. Adams D, Gonzalez-Duarte A, O'Riordan WD, Yang CC, Ueda M, Kristen AV, Tournev I, Schmidt HH, Coelho T, Berk JL, Lin KP, Vita G, Attarian S, Planté-Bordeneuve V, Mezei MM, Campistol JM, Buades J, Brannagan TH, Kim BJ, Oh J, Parman Y, Sekijima Y, Hawkins PN, Solomon SD, Polydefkis M, Dyck PJ, Gandhi PJ, Goyal S, Chen J, Strahs AL, Nochur SV, Sweetser MT, Garg PP, Vaishnaw AK, Gollob JA, Suhr OB. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 07 05; 379(1):11-21. PMID: 29972753.
     
  4. Benson MD, Waddington-Cruz M, Berk JL, Polydefkis M, Dyck PJ, Wang AK, Planté-Bordeneuve V, Barroso FA, Merlini G, Obici L, Scheinberg M, Brannagan TH, Litchy WJ, Whelan C, Drachman BM, Adams D, Heitner SB, Conceição I, Schmidt HH, Vita G, Campistol JM, Gamez J, Gorevic PD, Gane E, Shah AM, Solomon SD, Monia BP, Hughes SG, Kwoh TJ, McEvoy BW, Jung SW, Baker BF, Ackermann EJ, Gertz MA, Coelho T. Inotersen Treatment for Patients with Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018 07 05; 379(1):22-31. PMID: 29972757.
     
  5. Klimtchuk ES, Prokaeva T, Frame NM, Abdullahi HA, Spencer B, Dasari S, Cui H, Berk JL, Kurtin PJ, Connors LH, Gursky O. Unusual duplication mutation in a surface loop of human transthyretin leads to an aggressive drug-resistant amyloid disease. Proc Natl Acad Sci U S A. 2018 07 10; 115(28):E6428-E6436.View Related Profiles. PMID: 29941560.
     
  6. Mints YY, Doros G, Berk JL, Connors LH, Ruberg FL. Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience. ESC Heart Fail. 2018 Oct; 5(5):772-779.View Related Profiles. PMID: 29916559.
     
  7. Copperman TS, Truong MT, Berk JL, Sobel RK. External beam radiation for localized periocular amyloidosis: a case series. Orbit. 2018 Jun 11; 1-7.View Related Profiles. PMID: 29889595.
     
  8. Jhaveri T, Sarosiek S, Ruberg FL, Siddiqi O, Berk JL, Sanchorawala V. Once AL amyloidosis: not always AL amyloidosis. Amyloid. 2018 Jun; 25(2):139-140.View Related Profiles. PMID: 29516761.
     
  9. Phull P, Sanchorawala V, Connors LH, Doros G, Ruberg FL, Berk JL, Sarosiek S. Monoclonal gammopathy of undetermined significance in systemic transthyretin amyloidosis (ATTR). Amyloid. 2018 Mar; 25(1):62-67.View Related Profiles. PMID: 29424556.
     
  10. Hanson JLS, Arvanitis M, Koch CM, Berk JL, Ruberg FL, Prokaeva T, Connors LH. Use of Serum Transthyretin as a Prognostic Indicator and Predictor of Outcome in Cardiac Amyloid Disease Associated With Wild-Type Transthyretin. Circ Heart Fail. 2018 Feb; 11(2):e004000.View Related Profiles. PMID: 29449366.
     
Showing 10 of 83 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 83 publications over 23 distinct years, with a maximum of 10 publications in 2017 and 2018

YearPublications
19871
19911
19931
19942
19962
19983
19993
20002
20012
20023
20032
20043
20054
20071
20101
20117
20125
20135
20144
20157
20164
201710
201810
In addition to these self-described keywords below, a list of MeSH based concepts is available here.

amyloid lung disease
amyloidosis
familial amyloidotic polyneuropathy
pleural effusions
pulmonary fibrosis
tracheobronchial amyloidosis
Contact for Mentoring:

72 E. Concord St Housman (R)
Boston MA 02118
Google Map


Berk's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department